As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Investors in Ocular Therapeutix Inc (Symbol: OCUL) saw new options begin trading this week, for the June 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Investors in Ocular Therapeutix Inc (Symbol: OCUL) saw new options become available today, for the April 2026 expiration. One of the key data points that goes into the price an option buyer is willing ...

DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Wondering if Ocular Therapeutix at around US$7.78 is offering fair value right now, or if the recent volatility is masking a better entry point for long term investors. The stock has seen a 12.4% ...

Event-driven snapshot of Ocular Therapeutix Ocular Therapeutix (OCUL) has been drawing attention after recent share price swings, including a 6.8% decline over the past day, offset by a 14.9% gain ...

Ocular Therapeutix Inc (NASDAQ:OCUL) shares are trading lower by 13.3% to $7.63 Monday afternoon after the company reported worse-than-expected first-quarter financial results. What To Know: Ocular ...

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about ...